#USA #Cambridge #HBM9378 #Harbour BioMed #asthma

HBM9378/WIN378: A Breakthrough in Asthma Treatment

In the realm of biopharmaceuticals, exciting developments have unfolded with the announcement from Harbour BioMed regarding their latest treatment for asthma, HBM9378/WIN378. With positive results emerging from the Phase 2 POLARIS-1 study, this ultra-long-acting antibody targeting Thymic Stromal Lymphopoietin (TSLP) has shown considerable promise, paving the way for Phase 3 clinical trials.

Overview of the POLARIS-1 Study

Harbour BioMed’s POLARIS-1 study enrolled a total of 147 patients suffering from uncontrolled moderate-to-severe asthma. The interim analysis, reported on the first 98 participants, revealed significant efficacy metrics, highlighting the potential impact of HBM9378/WIN378 on asthma management. This novel monoclonal antibody is engineered to enhance binding efficacy and prolong its half-life, offering a biotherapeutic option that is administered bi-annually.

Key Findings: Efficacy and Safety

The results from the interim analysis were particularly encouraging. HBM9378/WIN378 demonstrated:

• - A substantial mean increase in Forced Expiratory Volume in one second (FEV1) of up to 174 mL, with a placebo-adjusted mean increase reaching 256 mL (p=0.033).
• - Significant reductions in fractional exhaled nitric oxide (FeNO), an important marker of airway inflammation, showing up to 24 ppb reduction (p=0.006).
• - A decrease in mean blood eosinophil count by up to 200 cells/µL, translating to a 51% reduction (p<0.0001).

These effects were observed promptly, with noticeable improvements by Week 2 and sustained through Week 24 after a single dose. Additionally, HBM9378/WIN378 displayed a favorable safety profile, with no serious adverse events linked to the treatment, and a balanced occurrence of side effects between the treatment and placebo groups.

Phase 3 Trials and Future Directions

Encouraged by these findings, Harbour BioMed has initiated the first Phase 3 study to further evaluate the efficacy of HBM9378/WIN378, focusing on two doses administered bi-annually. There is also an upcoming second Phase 3 trial slated for the first half of 2027, underscoring the commitment to bringing this innovative solution to patients struggling with asthma exacerbations.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, expressed optimism regarding the progress of HBM9378/WIN378, emphasizing its potential to significantly improve lung function and airway inflammation management. He remarked on the unique capability of this drug to effectively inhibit TSLP signaling, which plays a critical role in various immunological conditions, including asthma.

Conclusion

The journey towards enhanced asthma treatment options is well underway with HBM9378/WIN378. As the biopharmaceutical landscape evolves, this novel therapeutic approach represents a significant stride forward in patient care, potentially transforming the lives of those living with chronic respiratory diseases. Time will tell how the results of the upcoming trials will further substantiate these groundbreaking findings and provide new hope for asthma patients worldwide.